• 1
    Karnak I, Senocak ME, Ciftci AO, Caglar M, Bingol-Kologlu M, Tanyel FC, Buyukpamukcu N. Inflammatory myofibroblastic tumor in children: diagnosis and treatment. J Pediatr Surg 2001; 36: 90812.
  • 2
    Debelenko LV, Arthur DC, Pack SD, Helman LJ, Schrump DS, Tsokos M. Identification of CARS-ALK fusion in primary and metastatic lesions of an inflammatory myofibroblastic tumor. Lab Invest 2003; 83: 125565.
  • 3
    Lacoste-Collin L, Roux FE, Gomez-Brouchet A, Despeyroux ML, Uro-Coste E, Coindre JM, Delisle MB. Inflammatory myofibroblastic tumor: a spinal case with aggressive clinical course and ALK overexpression. Case report. J Neurosurg Spine 2003; 98: 21821.
  • 4
    Petridis AK, Hempelmann RG, Hugo HH, Eichmann T, Mehdorn HM. Metastatic low-grade inflammatory myofibroblastic tumor (IMT) in the central nervous system of a 29-year-old male patient. Clin Neuropathol 2004; 23: 15866.
  • 5
    Griffin CA, Hawkins AL, Dvorak C, Henkle C, Ellingham T, Perlman EJ. Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors. Cancer Res 1999; 59: 277680.
  • 6
    Lawrence B, Perez-Atayde A, Hibbard MK, Rubin BP, Dal Cin P, Pinkus JL, Xiao S, Yi ES, Fletcher CD, Fletcher JA. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol 2000; 157: 37784.
  • 7
    Bridge JA, Kanamori M, Ma Z, Pickering D, Hill DA, Lydiatt W, Lui MY, Colleoni GW, Antonescu CR, Ladanyi M, Morris SW. Fusion of the ALK gene to the clathrin heavy chain gene, CLTC, in inflammatory myofibroblastic tumor. Am J Pathol 2001; 159: 4115.
  • 8
    Cools J, Wlodarska I, Somers R, Mentens N, Pedeutour F, Maes B, De Wolf-Peeters C, Pauwels P, Hagemeijer A, Marynen P. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2002; 34: 35462.
  • 9
    Debiec-Rychter M, Marynen P, Hagemeijer A, Pauwels P. ALK-ATIC fusion in urinary bladder inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2003; 38: 18790.
  • 10
    Ma Z, Hill DA, Collins MH, Morris SW, Sumegi J, Zhou M, Zuppan C, Bridge JA. Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer 2003; 37: 98105.
  • 11
    Coffin CM, Patel A, Perkins S, Elenitoba-Johnson KS, Perlman E, Griffin CA. ALK1 and p80 expression and chromosomal rearrangements involving 2p23 in inflammatory myofibroblastic tumor. Mod Pathol 2001; 14: 56976.
  • 12
    Cook JR, Dehner LP, Collins MH, Ma Z, Morris SW, Coffin CM, Hill DA. Anaplastic lymphoma kinase (ALK) expression in the inflammatory myofibroblastic tumor: a comparative immunohistochemical study. Am J Surg Pathol 2001; 25: 136471.
  • 13
    Mandahl N, Heim S, Arheden K, Rydholm A, Willen H, Mitelman F. Three major cytogenetic subgroups can be identified among chromosomally abnormal solitary lipomas. Hum Genet 1988; 79: 2038.
  • 14
    Mitelman F, ed. ISCN: an international system for human cytogenetic nomenclature. Basel: S Karger, 1995.
  • 15
    Andreasson P, Johansson B, Arheden K, Billström R, Mitelman F, Höglund M. Deletions of CDKN1B and ETV6 in acute myeloid leukemia and myelodysplastic syndromes without cytogenetic evidence of 12p abnormalities. Genes Chromosomes Cancer 1997; 19: 7783.
  • 16
    Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor, New York: Cold Spring Harbor Laboratory Press, 1989.
  • 17
    Shugrue CA, Kolen ER, Peters H, Czernik A, Kaiser C, Matovcik L, Hubbard AL, Gorelick F. Identification of the putative mammalian orthologue of Sec31P, a component of the COPII coat. J Cell Sci 1999; 112: 454756.
  • 18
    Tang BL, Zhang T, Low DY, Wong ET, Horstmann H, Hong W. Mammalian homologues of yeast sec31p. An ubiquitously expressed form is localized to endoplasmic reticulum (ER) exit sites and is essential for ER-Golgi transport. J Biol Chem 2000; 275: 13597604.
  • 19
    Kirchhausen T. Clathrin. Annu Rev Biochem 2000; 69: 6994.
  • 20
    Mousavi SA, Malerod L, Berg T, Kjeken R. Clathrin-dependent endocytosis. Biochem J 2004; 377: 116.
  • 21
    Duden R. ER-to-Golgi transport: COP I and COP II function. Mol Membr Biol 2003; 20: 197207.
  • 22
    Smith TF, Gaitatzes C, Saxena K, Neer EJ. The WD repeat: a common architecture for diverse functions. Trends Biochem Sci 1999; 24: 1815.
  • 23
    Li D, Roberts R. WD-repeat proteins: structure characteristics, biological function, and their involvement in human diseases. Cell Mol Life Sci 2001; 58: 208597.
  • 24
    Duyster J, Bai RY, Morris SW. Translocations involving anaplastic lymphoma kinase (ALK). Oncogene 2001; 20: 562337.
  • 25
    Armstrong F, Duplantier MM, Trempat P, Hieblot C, Lamant L, Espinos E, Racaud-Sultan C, Allouche M, Campo E, Delsol G, Touriol C. Differential effects of X-ALK fusion proteins on proliferation, transformation, and invasion properties of NIH3T3 cells. Oncogene 2004; 23: 607182.
  • 26
    Rodrigues GA, Park M. Oncogenic activation of tyrosine kinases. Curr Opin Genet Dev 1994; 4: 1524.
  • 27
    Bischof D, Pulford K, Mason DY, Morris SW. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 1997; 17: 231225.
  • 28
    Coffin CM, Fletcher JA. Inflammatory myofibroblastic tumour. In: Fletcher CDM, Unni KK, Mertens F, eds. Pathology and genetics of tumours of soft tissue and bone. Lyon: IARC Press, 2002. 913.